TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SW1WRH2
| Market Closed - Deutsche Boerse AG 20:39:21 17/05/2024 BST | ||
| 11.74 EUR | -3.61% |
|
| Current month | -29.95% | ||
| 1 month | -29.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 11.74 | -3.61% |
| 16/05/24 | 12.18 | -2.01% |
| 15/05/24 | 12.43 | -7.10% |
| 14/05/24 | 13.38 | +1.13% |
| 13/05/24 | 13.23 | -5.09% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 08:39 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SW1WRH |
| ISIN | DE000SW1WRH2 |
| Date issued | 04/08/2023 |
| Strike | 570.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.71 € |
|---|---|
| Lowest since issue | 11.4 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
